Alfuzosin

Evidence Level: L5

Predicted Indications: 10

Alfuzosin
Alfuzosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita

## Pharmacist Assessment Report

Alfuzosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Alfuzosin is a marketed alpha-1 adrenergic blocker. It acts on prostatic and bladder-neck smooth muscle and is generally used for benign prostatic hyperplasia (BPH) symptoms. The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but there are 0 clinical trials and 0 publications supporting this direction. The high score looks like a graph-embedding artifact rather than clinical support.

Quick Overview

Item	Content
Original Indication	Not stated in the Evidence Pack (BPH per general drug knowledge)
Predicted New Indication	Ambras type hypertrichosis universalis congenita
TxGNN Prediction Score	99.999% (model rank 47)
Evidence Level	L5
US Market Status	✓ Marketed
Number of NDAs	16 authorizations (the ones listed are generic ANDAs)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known information, alfuzosin is a selective (uroselective) alpha-1 adrenergic antagonist. It relaxes smooth muscle in the prostate and bladder neck.

The original and predicted indications have little in common. Ambras syndrome is a rare congenital disorder of hair-follicle development. Alpha-1 signaling has no known role in it, and blockade is not expected to change hair growth.

The near-1.0 score most likely reflects graph proximity to other hair-related disease nodes. The other hair-related predictions (hypertrichosis, hair shaft abnormality, trichomegaly, hypotrichosis) show the same pattern. This prediction is not mechanistically reasonable on current information.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

(The 20 publications retrieved for the rank 3 prediction, a periodontal malformation syndrome, are general periodontitis literature. None mention alfuzosin, so they do not support any indication.)

US Market Information

The Evidence Pack lists no approved-indication text for any of these products.

Authorization Number	Product Name	Dosage Form	Manufacturer
ANDA079060	Alfuzosin Hydrochloride	Tablet, film coated, extended release	Rising Pharma Holdings, Inc.
ANDA079057	Alfuzosin Hydrochloride	Tablet, extended release	Northwind Health Company, LLC
ANDA079060	Alfuzosin Hydrochloride	Tablet, film coated, extended release	Aurobindo Pharma Limited
ANDA090284	Alfuzosin Hydrochloride	Tablet, extended release	Aphena Pharma Solutions - Tennessee, LLC
ANDA079057	Alfuzosin Hydrochloride	Tablet, extended release	Bryant Ranch Prepack

Safety Considerations

Please refer to the package insert for safety information. No drug interaction records were found in the Evidence Pack.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical or literature evidence, and no plausible mechanistic link between alpha-1 blockade and congenital hair-follicle development. The evidence level is L5, so the score reflects model prediction only.

To proceed, the following is needed:

A credible mechanistic hypothesis linking alpha-1 adrenergic signaling to the disease, supported by preclinical data
Detailed mechanism of action data (MOA) and package insert warnings and contraindications
Review of the other top-10 predictions for this drug. All are also L5 and lack a plausible mechanism, so none is a strong repurposing candidate on current evidence

This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.